A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella

Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. The intratumoral administration of these repurposed vaccines can induce immune cell infiltration into the treated tumor. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR)...

Full description

Bibliographic Details
Main Authors: Manlio Fusciello, Erkko Ylösmäki, Sara Feola, Arttu Uoti, Beatriz Martins, Karri Aalto, Firas Hamdan, Jacopo Chiaro, Salvatore Russo, Tapani Viitala, Vincenzo Cerullo
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Molecular Therapy: Oncolytics
Subjects:
oncolytic viruses
cancer vaccines
Priorix
mumps
measles
rubella
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770522000547

Similar Items

Similar Items